Baidu
map

《2015年St.Gallen早期乳腺癌国际专家共识》之手术治疗解读

2015-07-10 吴克瑾 陆云殊 UWe.Köhler(德国) 上海交通大学医学院附属新华医院普外科

2015年第14届St.Gallen国际乳腺癌大会,来自135个国家地区的乳腺肿瘤各领域专家(包括外科、肿瘤放疗科、病理科、影像科、肿瘤科等)对200多个关于早期乳腺癌治疗的临床决策问题进行了投票表决。肿瘤学年鉴杂志(Annals of Oncology)于2015-05-04正式发表了《2015年St.Gallen早期乳腺癌国际专家共识》。该共识中早期乳腺癌的手术治疗仍然延续了“减少手术创伤

2015年第14届St.Gallen国际乳腺癌大会,来自135个国家地区的乳腺肿瘤各领域专家(包括外科、肿瘤放疗科、病理科、影像科、肿瘤科等)对200多个关于早期乳腺癌治疗的临床决策问题进行了投票表决。肿瘤学年鉴杂志(Annals of Oncology)于2015-05-04正式发表了《2015年St.Gallen早期乳腺癌国际专家共识》。该共识中早期乳腺癌的手术治疗仍然延续了“减少手术创伤但不降低治疗效果”这一趋势,根据最新可靠的临床研究结果,更新了保乳切缘及相对禁忌证的概念,并明确3个及以上前哨淋巴结的宏转移是划分高风险腋窝淋巴结转移的可靠标准。随着前哨淋巴结活检技术的常规开展,专家组开始关注是否可免除前哨淋巴结阴性病人的手术创伤,术前超声检测前哨淋巴结并穿刺活检的临床研究已有开展,未来的研究结果可能进入共识。

1、原发灶的手术

1.1保乳手术切缘的定义  2013年版该共识中近3/4专家认为最小可接受的切缘为“无浸润性肿瘤印染”,其余的大部分专家认为可接受最小1mm的无瘤切缘。2015年版共识支持最小可接受切缘为“无浸润性肿瘤或导管原位癌(DCIS)印染”比较两版共识,存在两点更新。其一,不再提及1mm无瘤切缘,达到“无浸润性肿瘤印染”即可;其二,切缘加入了“无DCIS印染”未提及小叶原位癌(lobular carcinoma in situ,LCIS)。

2015年版共识有关切缘的更新和完善很大程度上参考了2014年美国外科肿瘤学会放射肿瘤分会关于保乳手术切缘的指南。专家组支持将无瘤切缘宽度定义为“无浸润性肿瘤印染”的依据有包括:(1)NSABP B06试验将无瘤切缘定义为无肿瘤印染,对接受系统治疗的病人随访12年的结果提示,同侧乳房局部复发率(ipsilateral breast tumor recurrence,IBTR)为5%,这与保乳手术总体IBTR 5.3%接近;(2)技术限制造成切缘评估存在不确定性,如标本取出后形态的改变,影像检査过程中的挤压,染料浸染的深度对病理科医生正确判断切缘造成的困难等;(3)根据包含19个临床研究、分析不同切缘宽度(1mm、2mm、5mm)与IBTR关系的Meta分析结果,专家组认为无统计数据证实IBTR与切缘宽度有关,也无证据显示IBTR的下降与无瘤切缘宽度的增加有相关趋势;(4)大部分将无瘤切缘定义为“无肿瘤印染”的放射学随机试验结果提示,全乳放疗后的局部瘤床加量照射显著降低了IBTR。全乳放射治疗的照射方法、分割方式和瘤床加量剂量不应根据切缘宽度决定。以上四项依据弱化了具体切缘宽度与IBTR的相关性。此外,已有证据明确显示切缘DCIS会增加IBTR,而切缘LCIS却对IBTR无影响。因此,2015年版共识将无瘤切缘简单而清晰地定义为“无浸润性肿瘤或DCIS印染”。

1.2保乳手术的绝对禁忌证  无更新。重复切取切缘有浸润性癌或DCIS残留以及保乳术后无计划行放疗仍为绝对禁忌证。

1.3保乳手术的相对禁忌证  2013年版共识中的保乳相对禁忌证(小叶组织来源、广泛导管内成分、年轻、多灶或多中心和不良生物学亚型)在2015年版共识中不再提及。专家组认为只要切缘达到“无浸润性肿瘤或DCIS印染”标准,以及有计划行术后放疗,具有以上“相对禁忌证”病人同样可行保乳手术。

2、腋窝的手术

2.1前哨淋巴结1~2个宏转移的处理  根据最新发布的临床研究结果,符合ACOSOG Z0011标准的病人中有84%仅需行前哨淋巴结活检(sentinal lymph node biopsy,SLNB),随访13个月无腋窝复发,大大减少了不必要的腋窝损伤。因此,专家组支持将Z0011的结果在临床实践中推广。绝大部分专家明确赞成行保乳及术后标准放疗病人可免除腋窝淋巴结清扫(axillary lymph node dissection,ALND)。如行全乳切除术后无计划放疗,专家组一致同意需行ALND。但对于全乳切除术后有计划放疗病人是否需行ALND,专家组的意见一分为二(此结果与2013年版共识相同)。本文作者之一德国Klinikum St.Georg医院的UWe.KHhler教授是2015年St.Gallen共识的投票专家,作为乳腺外科领域专家他认为此类病人无需行ALND。对于两届共识都未解决此分歧的原因,他认为相当部分专家组成员来自非外科领域,且目前尚无足够循证医学依据帮助专家组做出明确的判断。

2.2前哨淋巴结3个及以上宏转移的处理  对3个及以上前哨淋巴结转移病人的进一步腋窝清扫结果显示,有72%的病人存在更多的淋巴结转移。因此,该界限是可靠的划分高危腋淋巴结转移病人的指标。

2.3临床腋窝淋巴结阳性者需谨慎对待,专家组认为在新辅助化疗实现降期后,仍可行前哨淋巴结活检。但在这种情况下,即使只有一个前哨淋巴结存在转移,即需要行腋窝淋巴结清扫。

2.4免除前哨淋巴结阴性病人手术活检的可能性  2015年版共识未明确该问题,但已有讨论。在符合Z0011标准的病人中,仅18%证实有前哨淋巴结转移,其余近80%前哨淋巴结无转移的病人存在腋窝过度损伤。同位素前哨淋巴结显影结合超声引导下穿刺活检判定前哨淋巴结转移的研究已有开展,但尚无足够依据。

2015年版共识对保乳切缘做出了清晰的解释,并根据循证医学依据将保乳的适应证进一步拓宽,以利更多病人在不降低治疗效果的前提下减少不必要的手术损伤。Z0011试验的结果在临床实践中被证实是可行且可靠的。随着SLNB的推广,如何进一步避免不必要的前哨淋巴结手术活检损伤成为新的研究趋势,期待未来更多的临床研究回答这一问题。

作者:上海交通大学医学院附属新华医院普外科  吴克瑾  陆云殊  UWe.Köhler(德国)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1844456, encodeId=671b1844456dd, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Jul 29 00:28:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34520, encodeId=a4e5345207f, content=这篇文章不大理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34521, encodeId=ecce34521c8, content=不过这解读看来是很到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32441, encodeId=63dd32441c5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun Jul 12 16:35:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290568, encodeId=b182129056831, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328878, encodeId=fc3313288e8a4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32280, encodeId=4b1f32280fc, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Fri Jul 10 19:16:00 CST 2015, time=2015-07-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1844456, encodeId=671b1844456dd, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Jul 29 00:28:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34520, encodeId=a4e5345207f, content=这篇文章不大理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34521, encodeId=ecce34521c8, content=不过这解读看来是很到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32441, encodeId=63dd32441c5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun Jul 12 16:35:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290568, encodeId=b182129056831, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328878, encodeId=fc3313288e8a4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32280, encodeId=4b1f32280fc, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Fri Jul 10 19:16:00 CST 2015, time=2015-07-10, status=1, ipAttribution=)]
    2015-08-05 hlycom3356

    这篇文章不大理解

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1844456, encodeId=671b1844456dd, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Jul 29 00:28:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34520, encodeId=a4e5345207f, content=这篇文章不大理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34521, encodeId=ecce34521c8, content=不过这解读看来是很到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32441, encodeId=63dd32441c5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun Jul 12 16:35:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290568, encodeId=b182129056831, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328878, encodeId=fc3313288e8a4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32280, encodeId=4b1f32280fc, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Fri Jul 10 19:16:00 CST 2015, time=2015-07-10, status=1, ipAttribution=)]
    2015-08-05 hlycom3356

    不过这解读看来是很到位

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1844456, encodeId=671b1844456dd, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Jul 29 00:28:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34520, encodeId=a4e5345207f, content=这篇文章不大理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34521, encodeId=ecce34521c8, content=不过这解读看来是很到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32441, encodeId=63dd32441c5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun Jul 12 16:35:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290568, encodeId=b182129056831, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328878, encodeId=fc3313288e8a4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32280, encodeId=4b1f32280fc, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Fri Jul 10 19:16:00 CST 2015, time=2015-07-10, status=1, ipAttribution=)]
    2015-07-12 huaxipanxing

    看看

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1844456, encodeId=671b1844456dd, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Jul 29 00:28:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34520, encodeId=a4e5345207f, content=这篇文章不大理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34521, encodeId=ecce34521c8, content=不过这解读看来是很到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32441, encodeId=63dd32441c5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun Jul 12 16:35:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290568, encodeId=b182129056831, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328878, encodeId=fc3313288e8a4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32280, encodeId=4b1f32280fc, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Fri Jul 10 19:16:00 CST 2015, time=2015-07-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1844456, encodeId=671b1844456dd, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Jul 29 00:28:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34520, encodeId=a4e5345207f, content=这篇文章不大理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34521, encodeId=ecce34521c8, content=不过这解读看来是很到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32441, encodeId=63dd32441c5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun Jul 12 16:35:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290568, encodeId=b182129056831, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328878, encodeId=fc3313288e8a4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32280, encodeId=4b1f32280fc, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Fri Jul 10 19:16:00 CST 2015, time=2015-07-10, status=1, ipAttribution=)]
    2015-07-12 膀胱癌
  7. [GetPortalCommentsPageByObjectIdResponse(id=1844456, encodeId=671b1844456dd, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Jul 29 00:28:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34520, encodeId=a4e5345207f, content=这篇文章不大理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34521, encodeId=ecce34521c8, content=不过这解读看来是很到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Wed Aug 05 11:33:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32441, encodeId=63dd32441c5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun Jul 12 16:35:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290568, encodeId=b182129056831, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328878, encodeId=fc3313288e8a4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jul 12 06:28:00 CST 2015, time=2015-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32280, encodeId=4b1f32280fc, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Fri Jul 10 19:16:00 CST 2015, time=2015-07-10, status=1, ipAttribution=)]
    2015-07-10 cmn

    看看

    0

相关资讯

Cancer Res:鉴别出可促进乳腺癌转移的特殊蛋白

近日,一项发表于国际杂志Cancer Research上的研究论文中,来自隆德大学的研究者通过研究表示,机体肿瘤血管中活化素样受体激酶(ALK1)蛋白处于较高水平的乳腺癌患者或更易发生癌症转移,因此开发抑制ALK1的通路的技术或可作为治疗转移性乳腺癌的新疗法。 研究者Kristian Pietras说道,尽管乳腺癌在早期检测后尽快给予治疗会使得患者的预后良好,但癌症转移是引发90%癌症相关死亡的

Lancet:依西美坦和他莫昔芬治疗女性绝经前早期乳腺癌并接受卵巢抑制的疗效

    背景  TEXT和SOFT试验的疗效相结合分析显示依西美坦加卵巢功能抑制(OFS)与他莫昔芬加上OFS相比有显著无病生存利益。研究人员目前从这些试验的患者报告结果。    方法  在2003年11月7日和2011年4月7日之间,4717例绝经前激素受体阳性的乳腺癌患者被纳入TEXT或SOFT研究接受5年的依西美坦加OFS或他莫昔芬

Nature:黄体酮可提高乳腺癌患者的生存率

乳腺癌是一种常见的癌症。在澳洲,每八位女性中就有一位乳腺癌患者,而且,每天有七位乳腺癌患者死亡。在美国平均每年有18万5千位妇女患乳腺癌,并有4万4***死于这种疾病。近日,来自澳洲Adelaide大学及英国剑桥的研究人员发现,介导女性性激素(雌激素ER和黄体酮)活性的受体是如何与DNA相互作用,从而抑制了大多数乳腺癌生长的。相关研究结果在线发表于Nature杂志上。研究人员们用了最先进的DNA读取

Br J Cancer:乳腺癌高危女性需戒酒

已有研究发现,饮酒可通过增加乳腺密度的机制来增加患乳腺癌患病风险,但饮酒量与乳腺癌密度之间是如何影响乳腺癌患病风险尚不清楚。 研究人员进行了一项以人群为基础的横断面研究,收纳了来自瑞典年龄在40-74岁的53060名女性。使用问卷调查来评定饮酒量。乳腺密度则用自动测量体积的方法测量。运用Tyrer-Cuzick预测模型来评估未来10年女性患乳腺癌的风险。线性回归模型用来评估饮酒量和乳腺密度和乳腺

Nat Commun:治疗癌症新思路:移除对肿瘤血管形成关键的蛋白

近日,来自利兹大学等处的科学家通过研究发现,一种特殊蛋白或可诱发乳腺癌中肿瘤血管的生长,从而促进乳腺癌扩散到大脑中,而乳腺癌向大脑中扩散是其最常见的一种扩散手段,相关研究发表于Nature Communications上。研究者Georgia Mavria表示,通过抑制小鼠模型中DOCK4蛋白,肿瘤血管中的特殊部分就不能够快速形成,从而就会降低肿瘤的生长速度,我们想通过研究阐明肿瘤形成和生长的机制

Lab Invest:每日服用阿司匹林或可有效抑制乳腺癌的发展

近日,一项刊登在国际杂志Laboratory Investigation上的研究论文中,来自堪萨斯城退伍军人医疗中心的研究人员通过研究发现,每日服用一定的剂量的阿司匹林或可有效阻断乳腺癌的生长,此前研究显示阿司匹林或许对结肠癌、胃肠道癌、前列腺癌等其它癌症均有一定的抑制作用。Banerjee教授说道,在癌症治疗前期阶段一旦尽力去治疗患者,一般肿瘤都会有希望被有效遏制住,但由于癌症干细胞的存在,其往

Baidu
map
Baidu
map
Baidu
map